Evidence map›Paper›PMID 31137622›Full record

ReviewMolecules (Basel, Switzerland)2019

Recent Developments in Antibacterial Therapy: Focus on Stimuli-Responsive Drug-Delivery Systems and Therapeutic Nanoparticles.

Roberto Canaparo, Federica Foglietta, Francesca Giuntini, Carlo Della Pepa, Franco Dosio, Loredana Serpe

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Roberto CanaparoDepartment of Drug Science and Technology, University of Torino, 10125 Torino, Italy. roberto.canaparo@unito.it.
Federica FogliettaDepartment of Drug Science and Technology, University of Torino, 10125 Torino, Italy. federica.foglietta@unito.it.
Francesca GiuntiniSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 2AJ, UK. f.giuntini@ljmu.ac.uk.ORCID 0000-0002-3444-8183
Carlo Della PepaDepartment of Drug Science and Technology, University of Torino, 10125 Torino, Italy. carlo.dellapepa@unito.it.
Franco DosioDepartment of Drug Science and Technology, University of Torino, 10125 Torino, Italy. franco.dosio@unito.it.ORCID 0000-0003-1128-9922
Loredana SerpeDepartment of Drug Science and Technology, University of Torino, 10125 Torino, Italy. loredana.serpe@unito.it.
University of Turin · ITLiverpool John Moores University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional drugs used for antibacterial therapy display several limitations. This is not due to antibiotics being ineffective, but rather due to their low bioavailability, limited penetration to sites of infection and the rise of drug-resistant bacteria. Although new delivery systems (e.g., nanoparticles) that are loaded with antibacterial drugs have been designed to overcome these limitations, therapeutic efficacy does not seem to have improved. Against this backdrop, stimuli-responsive antibiotic-loaded nanoparticles and materials with antimicrobial properties (nanoantibiotics) present the ability to enhance therapeutic efficacy, while also reducing drug resistance and side effects. These stimuli can either be exogenous (e.g., light, ultrasound) or endogenous (e.g., pH, variation in redox gradient, enzymes). This promising therapeutic approach relies on advances in materials science and increased knowledge of microorganism growth and biofilm formation. This review provides an overview in the field of antibacterial drug-delivery systems and nanoantibiotics that benefit from a response to specific triggers, and also presents a number of future prospects.

Indexed as

Drug Delivery SystemsAnti-Bacterial AgentsLightNanoparticlesTemperatureAnti-Bacterial Agentsantibiotics drug delivery systemsbacterial biofilmsdrug delivery systemsmulti-drug resistant bacteriananoantibioticsnanoparticlesstimuli-responsive antibiotic-loaded nanoparticlesstimuli-responsive nanoantibioticsstimuli-responsive nanoparticles

Identifiers

PMID31137622
PMCPMC6572634
OpenAlexW2945466911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.